The Uromigos

Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.

Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025

Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA

Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC

Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025

Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE

Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study

Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer

Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer

Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.

Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.

Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.

5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました！！評価はいかに？

Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.

ASCO2025の注目演題を取り上げ解説、ディスカッションしました！

Brian, Tom and Silke discuss their highlights form ASCO 2025

Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.

Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025

Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone

Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.

Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.

Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.

Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation

Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.

David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.

Practice Changing?  独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。

Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025

日本と海外の違いはあるのか？mHSPCとmCRPCのUromigos Scoreについて激論！！

Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica distintas opciones de tratamiento en varios escenarios de cáncer de próstata metastásico

Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.

Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.

Viktor Grunwald joins to discuss the new data session from EIKCS

Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC

Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting

今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて深い議論をしました！！

Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China

Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.

Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.